Aug. 20 (Bloomberg) -- Cytos Biotechnology AG, the Swiss developer of vaccines against allergies and nicotine addiction, expects to sell rights to an experimental treatment for hypertension in the second half of next year.
Aug. 20 (Bloomberg) -- Cytos Biotechnology AG, the Swiss developer of vaccines against allergies and nicotine addiction, expects to sell rights to an experimental treatment for hypertension in the second half of next year.
